Pricing
  1. JP-listed companies
  2. PhoenixBio Co.,Ltd.
  3. Financials
  4. Total cash & short-term investments

PhoenixBio Co.,Ltd.【JP:6190】

Market cap
¥1.8B
P/E ratio
16.8x
Phoenix Bio provides pharmaceutical testing services using PXB mice with human liver cells to help drug companies predict how medicines work in people.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndTotal cash & short-term investments (Million JPY)YoY (%)
Mar 31, 20251,150-16.97%
Mar 31, 20241,385-10.94%
Mar 31, 20231,555+17.34%
Mar 31, 20221,326-0.17%
Mar 31, 20211,328-25.21%
Mar 31, 20201,775+170.36%
Mar 31, 2019657-29.61%
Mar 31, 2018933-42.95%
Mar 31, 20171,635+1.97%
Mar 31, 20161,604+140.10%
Mar 31, 2015668

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)